CAV1 and prostate cancer: We considered the implications of our findings of this adaptive Cav-1-mediated glycosphingolipid mechanism and developed the hypothesis that targeting of the ceramide to glycosphingolipid conversion may represent an actionable metabolic vulnerability in prostate cancer.